Products
Pre-made Sulesomab benchmark antibody (Radiolabelled antibody, anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-INN-1000
Pre-made Sulesomab benchmark antibody (Radiolabelled antibody, anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) therapeutic antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Technetium (99mTc) sulesomab (trade name LeukoScan) is a radio-pharmaceutical composed of anti-human mouse monoclonal antibody[1] that targets the granulocyte associated NCA-9 cell antigen and a conjugated technetium-99m radionuclide. After intravenous administration, Leukoscan enables sensitive and specific whole body measurement of granulocyte infiltration and activation by gamma camera imaging of 99mTc-antibody bound cells.[2] Total clearance of LeukoScan from blood samples after administration and imaging has been reported at 48 hour time points indicating limited retention of the agent in circulation[3]
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-INN-1000-1mg | 1mg | 3090 | ||
| GMP-Bios-INN-1000-10mg | 10mg | Inquiry | ||
| GMP-Bios-INN-1000-100mg | 100mg | Inquiry | ||
| GMP-Bios-INN-1000-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Sulesomab Biosimilar, Radiolabelled Antibody: Anti-Nca-90 (Nonspecific Cross- Reacting Antigens 90Kda Glycoproteins, Granulocyte Cell Antigen) therapeutic antibody |
| INN Name | Sulesomab |
| Target | NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) |
| Format | Radiolabelled antibody |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | Fab' - G1 - nd |
| VD LC | Fab' - G1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Immunomedics Inc. (Morris Plains NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
